AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27859267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26000677 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiva VCF Treatment System
Number of subjects: 304
Study 26000677 — intervention group
Group type: COMPARATOR
Intervention: Balloon Kyphoplasty (BK)
Number of subjects: 304
Study 23758106 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils
Number of subjects: 24
Study 23758106 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine/stannous fluoride
Number of subjects: 24
Study 23758106 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine digluconate (0.12%)
Number of subjects: 24
Study 21570523 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management (DM) program that reduced readmissions by 21%
Number of subjects: 0
Study 21570523 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluated published DM programs
Number of subjects: 0
Study 21570523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled payments including care over 180 days
Number of subjects: 0
Study 19013521 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% timolol hydrogel
Number of subjects: 0
Study 19013521 — intervention group
Group type: COMPARATOR
Intervention: 0.5% aqueous timolol
Number of subjects: 0
Study 16684198 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided participation (GP) with printed guidelines for managing VLBW infant health problems.
Number of subjects: 31
Study 16684198 — intervention group
Group type: COMPARATOR
Intervention: Standard care with printed guidelines (GL) for managing VLBW infant health problems.
Number of subjects: 31
Study 16359800 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces Pain Scale-Revised (FPS-R)
Number of subjects: 112
Study 14615442 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotaped consultation (patients given audiotape)
Number of subjects: 628
Study 14615442 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotaped consultation (patients offered choice of receiving audiotape or not)
Number of subjects: 628
Study 14615442 — intervention group
Group type: COMPARATOR
Intervention: Audiotaped consultation (not audiotaped)
Number of subjects: 628
Study 14615442 — intervention group
Group type: COMPARATOR
Intervention: Audiotaped consultation (no audiotape given)
Number of subjects: 628
Study 9831777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF
Number of subjects: 30
Study 9831777 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% xylitol
Number of subjects: 30
Study 9831777 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% NaF plus 20% xylitol
Number of subjects: 30
Study 9831777 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 30
Study 7737135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) treatment (50-200 mg/day)
Number of subjects: 14
Study 7737135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) treatment (high doses)
Number of subjects: 14
Study 7737135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sister chromatid exchange (SCE) test
Number of subjects: 14
Study 7737135 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 14
Study 7737135 — intervention group
Group type: COMPARATOR
Intervention: Patients without chemotherapy (n=5)
Number of subjects: 14
Study 2407003 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PRED) therapy
Number of subjects: 67
Study 2407003 — intervention group
Group type: COMPARATOR
Intervention: No Prednisone (NOPRED) therapy
Number of subjects: 67
Study 2407003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 34415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (H1-receptor blocker)
Number of subjects: 4
Study 34415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-receptor blocker)
Number of subjects: 4
Study 34415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and Cimetidine (both intravenous)
Number of subjects: 4
Study 31274710 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete internal limiting membrane peeling (CP)
Number of subjects: 46
Study 31274710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fovea‐sparing internal limiting membrane peeling (FSP)
Number of subjects: 46
Study 31298350 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human basic fibroblast growth factor combined with compound polymyxin B ointment and local application of insulin
Number of subjects: 80
Study 31298350 — intervention group
Group type: COMPARATOR
Intervention: Compound polymyxin B ointment
Number of subjects: 80
Study 28525471 — intervention group
Group type: EXPERIMENTAL
Intervention: Discover arthroplasty
Number of subjects: 105
Study 28525471 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 105
Study 25849681 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 20
Study 25849681 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine infusion (NTG group)
Number of subjects: 20
Study 25849681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 23317314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner follow-up intervention
Number of subjects: 200
Study 23317314 — intervention group
Group type: COMPARATOR
Intervention: Standard model of follow-up care
Number of subjects: 200
Study 21786523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 95
Study 21786523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 95
Study 21786523 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 95
Study 19452097 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight-bearing and non-weight-bearing (water) exercise program (E)
Number of subjects: 125
Study 19452097 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 125
Study 17427617 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated peppermint oil
Number of subjects: 0
Study 17427617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination product of peppermint oil and caraway oil
Number of subjects: 0
Study 17427617 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of peppermint oil
Number of subjects: 0
Study 17427617 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil via enema
Number of subjects: 0
Study 17427617 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly recommended dosage of peppermint oil
Number of subjects: 0
Study 15584814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks with more complex or less familiar rules
Number of subjects: 0
Study 15584814 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus repetitions
Number of subjects: 0
Study 15584814 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-switching experiments
Number of subjects: 0
Study 11747323 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 37
Study 11747323 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 600 mg daily
Number of subjects: 37
Study 11747323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9010041 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 147
Study 9010041 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ibandronate
Number of subjects: 147
Study 9010041 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ibandronate
Number of subjects: 147
Study 8343314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg)
Number of subjects: 200
Study 8343314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8343314 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous aspirin use
Number of subjects: 200
Study 3511406 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 58
Study 30894560 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g high amylose RS2
Number of subjects: 19
Study 30894560 — intervention group
Group type: COMPARATOR
Intervention: Energy-matched control starch
Number of subjects: 19
Study 28535275 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse odds of sampling weights
Number of subjects: 0
Study 26269240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 147
Study 26269240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 24140455 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum specific intervention designed to address concerns about mood, stress and weight using cognitive‐behavioral techniques
Number of subjects: 300
Study 24140455 — intervention group
Group type: COMPARATOR
Intervention: Support-only condition designed to control for time and attention
Number of subjects: 300
Study 21609524 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI ≤ 2 group (n = 43)
Number of subjects: 129
Study 21609524 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI 3 group (n = 43)
Number of subjects: 129
Study 21609524 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 43)
Number of subjects: 129
Study 21609524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vWF at admission and vWF at the beginning of PCI
Number of subjects: 129
Study 19329015 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.125% bupivacaine with 20 microg/kg/hr midazolam (Group BM)
Number of subjects: 44
Study 19329015 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of 0.125% bupivacaine alone (Group B)
Number of subjects: 44
Study 17015404 — intervention group
Group type: EXPERIMENTAL
Intervention: Multislice computed tomography (CT) for the identification and quantification of aortic valvular stenosis (AS)
Number of subjects: 107
Study 17015404 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography for measuring the aortic valvular area (AVA)
Number of subjects: 107
Study 15026091 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement-based procedures
Number of subjects: 120
Study 15026091 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior severity
Number of subjects: 120
Study 15026091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rater experience
Number of subjects: 120
Study 15026091 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral function
Number of subjects: 120
Study 12065109 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA followed by EVBT
Number of subjects: 113
Study 9689267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.17 mg/kg i.v.
Number of subjects: 95
Study 9689267 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0.02 mg/kg i.v.
Number of subjects: 95
Study 7722565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 63
Study 2603894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 60
Study 2603894 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 60
Study 2603894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study 2603894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin and Doxycycline
Number of subjects: 60
Study 1198232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) tablets
Number of subjects: 0
Study 1198232 — intervention group
Group type: EXPERIMENTAL
Intervention: Desamino-oxy-tocin
Number of subjects: 0
Study 1198232 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin after amniotomy
Number of subjects: 0
Study 30170687 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 0.25% bupivacaine (40mL total)
Number of subjects: 90
Study 30170687 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 0.25% bupivacaine + 1/100,000 epinephrine (40mL total)
Number of subjects: 90
Study 30170687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28148296 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game (n=32)
Number of subjects: 103
Study 28148296 — intervention group
Group type: EXPERIMENTAL
Intervention: E-module (n=34)
Number of subjects: 103
Study 28148296 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (n=37)
Number of subjects: 103
Study 25600085 — intervention group
Group type: COMPARATOR
Intervention: 4 × 6 nmol Cat‐PAD
Number of subjects: 0
Study 25600085 — intervention group
Group type: COMPARATOR
Intervention: 8 × 3 nmol Cat‐PAD
Number of subjects: 0
Study 25600085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23221898 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with sodium valproate
Number of subjects: 40
Study 23221898 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) without sodium valproate
Number of subjects: 40
Study 21499923 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in SINERGIA VR simulator
Number of subjects: 42
Study 21499923 — intervention group
Group type: COMPARATOR
Intervention: Pre-training tests of novices
Number of subjects: 42
Study 21499923 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training tests of novices
Number of subjects: 42
Study 19369887 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Multiple Sclerosis Quality of Life Scale (LMSQoL)
Number of subjects: 69
Study 16442464 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program for hypoglycemia (intervention group)
Number of subjects: 207
Study 16442464 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient education on hypoglycemia (control group)
Number of subjects: 207
Study 15569893 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorders
Number of subjects: 500
Study 10815116 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (up to 300 mg/d)
Number of subjects: 312
Study 10815116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 312
Study 10815116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 10815116 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus imipramine
Number of subjects: 312
Study 10815116 — intervention group
Group type: COMPARATOR
Intervention: CBT plus placebo
Number of subjects: 312
Study 10815116 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 312
Study 10815116 — intervention group
Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 312
Study 10815116 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT combined with imipramine
Number of subjects: 312
Study 8839505 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fruit and -vegetable diets (approximately 16 mg/d carotenoids)
Number of subjects: 36
Study 8839505 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carotenoid diet with additional broccoli (205 g/d) for 5 days
Number of subjects: 36
Study 8839505 — intervention group
Group type: COMPARATOR
Intervention: Basic high-carotenoid diet alone
Number of subjects: 36
Study 1530752 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anesthesia with high doses of sufentanil
Number of subjects: 30
Study 1530752 — intervention group
Group type: COMPARATOR
Intervention: Lighter anesthesia with halothane and morphine
Number of subjects: 30
Study 6331157 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (MK-421, 10 to 20 mg bid)
Number of subjects: 39
Study 6331157 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 25 to 50 mg bid)
Number of subjects: 39
Study 6331157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (MK-421 + HCTZ)
Number of subjects: 39
Study 31552537 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-operative ambulation (EA, n=30)
Number of subjects: 60
Study 31552537 — intervention group
Group type: COMPARATOR
Intervention: Flat bed rest for 48 hours (BR, n=30)
Number of subjects: 60
Study 31429896 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 126
Study 31429896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 28633669 — intervention group
Group type: EXPERIMENTAL
Intervention: Program A (10 exercises recommended for general LBP)
Number of subjects: 39
Study 28633669 — intervention group
Group type: EXPERIMENTAL
Intervention: Program B (4 exercises designed specifically to improve LT muscular endurance)
Number of subjects: 39
Study 25945019 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 d moxifloxacin‐based sequential therapy (MOX‐ST group)
Number of subjects: 161
Study 25945019 — intervention group
Group type: COMPARATOR
Intervention: 14 d clarithromycin‐based sequential therapy (CLA‐ST group)
Number of subjects: 161
Study 23425374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led psycho-education program
Number of subjects: 96
Study 23425374 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 96
Study 22133942 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin
Number of subjects: 22
Study 22133942 — intervention group
Group type: COMPARATOR
Intervention: Conventional hybrid resin
Number of subjects: 22
Study 22133942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis
Number of subjects: 22
Study 22133942 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-placement saliva sample
Number of subjects: 22
Study 19359326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Programme (CDSMP) for 6 weeks; usual care included regular checkups at an outpatient clinic.
Number of subjects: 317
Study 19359326 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) consisting of regular checkups at an outpatient clinic.
Number of subjects: 317
Study 17075320 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (29 patients)
Number of subjects: 58
Study 17075320 — intervention group
Group type: COMPARATOR
Intervention: Control (29 patients)
Number of subjects: 58
Study 15006114 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 54
Study 10848740 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 microg g‐1) applied immediately before irradiation
Number of subjects: 37
Study 10848740 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 microg g‐1) applied immediately before irradiation
Number of subjects: 37
Study 10848740 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (untreated area)
Number of subjects: 37
Study 9358548 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinchilli Metric
Number of subjects: 390
Study 9358548 — intervention group
Group type: EXPERIMENTAL
Intervention: f1
Number of subjects: 390
Study 9358548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescigno Index (exponent = 3)
Number of subjects: 390
Study 9358548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescigno Index (exponent = 1)
Number of subjects: 390
Study 9358548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescigno Index (exponent = 1/3)
Number of subjects: 390
Study 9358548 — intervention group
Group type: COMPARATOR
Intervention: Typical criteria (AUC and Cmax)
Number of subjects: 390
Study 9358548 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinchilli Metric and f1
Number of subjects: 390
Study 1563426 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin-methylcellulose emulsion
Number of subjects: 0
Study 1563426 — intervention group
Group type: COMPARATOR
Intervention: Diluted iodine solution or barium suspension
Number of subjects: 0
Study 3908514 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (2 or 4 gm in children, 6 or 8 gm in adults)
Number of subjects: 123
Study 3675669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized antithrombin III concentrate Kybernin HS/P
Number of subjects: 13
Study 28726550 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 65
Study 28726550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 27663358 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (informing patients of a pharmacy‐based opioid disposal program)
Number of subjects: 79
Study 27663358 — intervention group
Group type: COMPARATOR
Intervention: Standard opioid prescription
Number of subjects: 79
Study 25514556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 48
Study 25514556 — intervention group
Group type: COMPARATOR
Intervention: Control group (high HBsAg levels)
Number of subjects: 48
Study 22589423 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg transdermal nicotine
Number of subjects: 87
Study 20642661 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (Group B)
Number of subjects: 65
Study 20642661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with fentanyl (Group BF)
Number of subjects: 65
Study 20642661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine (Group BC)
Number of subjects: 65
Study 20642661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with clonidine and fentanyl (Group BCF)
Number of subjects: 65
Study 18358260 — intervention group
Group type: EXPERIMENTAL
Intervention: Look AHEAD lifestyle intervention
Number of subjects: 0
Study 18358260 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program (DPP) lifestyle intervention
Number of subjects: 0
Study 16808801 — intervention group
Group type: EXPERIMENTAL
Intervention: Amelogenin proteins (Xelma)
Number of subjects: 123
Study 16808801 — intervention group
Group type: COMPARATOR
Intervention: Propylene glycol alginate 7%
Number of subjects: 123
Study 12952566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) rechallenge
Number of subjects: 613
Study 12952566 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus mitomycin C (MMC)
Number of subjects: 613
Study 11012052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspace cage and local autograft
Number of subjects: 54
Study 11012052 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest graft fusion
Number of subjects: 54